Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Erasca, Inc. (ERAS : NSDQ)

• Company Description    Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO. Number of Employees: 103

• Price / Volume Information    Yesterday's Closing Price: $2.27 Daily Weekly Monthly 20 Day Moving Average: 1,193,190 shares Shares Outstanding: 283.67 (millions) Market Capitalization: $643.93 (millions) Beta: 1.19 52 Week High: $3.30 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.81% -8.28% 12 Week 38.42% 32.67% Year To Date -9.56% -20.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3115 MERRYFIELD ROW SUITE 300 - SAN DIEGO,CA 92121 USA ph: 858-465-6511 fax: - ir@erasca.com http://www.erasca.com

• General Corporate Information    Officers Jonathan E. Lim - Chief Executive Officer; Chairman and Co-Founder David M. Chacko - Chief Financial Officer and Chief Business Officer Michael D. Varney - Chair of Research and Development and Director James A. Bristol - Director Alexander W. Casdin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29479A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 283.67 Most Recent Split Date: (:1) Beta: 1.19 Market Capitalization: $643.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 10.78% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.73 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 58.62% vs. Previous Quarter: -9.09% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -31.19 03/31/25 - -36.56 ROA 09/30/25 - - 06/30/25 - -26.34 03/31/25 - -31.08 Current Ratio 09/30/25 - - 06/30/25 - 11.03 03/31/25 - 12.35 Quick Ratio 09/30/25 - - 06/30/25 - 11.04 03/31/25 - 12.35 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 1.31 03/31/25 - 1.41 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©